968 F.3d 1323
Fed. Cir.2020Background
- The ’559 patent claims a method for operating a flow cytometer that detects signals from at least two detectors, converts those signals to n‑dimensional parameter data, rotationally (and optionally scale/translate) alters that data to increase spatial separation between overlapping populations, and then real‑time classifies and sorts individual particles.
- The asserted invention is aimed at improving discrimination (e.g., sex‑selection of sperm) where populations produce closely clustered signal data.
- In 2016 XY sued Trans Ova for infringement of multiple patents including the ’559 patent; Trans Ova moved for judgment on the pleadings under 35 U.S.C. § 101 as to the ’559 claims and separately moved to dismiss other patent claims as claim‑precluded based on a 2012 lawsuit.
- The district court held the asserted claims of the ’559 patent ineligible under § 101 (characterizing them as an abstract mathematical rotation of multi‑dimensional data) and dismissed claims based on the ’422, ’116, and ’769 patents as claim‑precluded.
- On appeal the Federal Circuit reversed the § 101 holding, concluding the claims are directed to a patent‑eligible improvement to flow cytometry (an applied, physical process), and vacated the claim‑preclusion dismissal because the district court failed to compare claim scope as required.
- The case was remanded: eligibility decision reversed; claim‑preclusion dismissal vacated and sent back for a proper scope comparison under SimpleAir/Senju principles.
Issues
| Issue | XY's Argument | Trans Ova's Argument | Held |
|---|---|---|---|
| §101 eligibility of asserted claims of U.S. Patent No. RE46,559 | Claims recite a patent‑eligible, concrete improvement to flow cytometry that applies mathematical transformations to improve real‑time classification and sorting. | Claims are directed to an abstract mathematical operation (rotating multi‑dimensional data) and lack an inventive concept. | Reversed: claims are not directed to an abstract idea; they recite a specific, applied method improving flow cytometry (no need to reach step two). |
| Claim preclusion as to U.S. Patents Nos. 6,732,422; 7,723,116; 8,652,769 | District court must compare the scope of the currently asserted claims to those asserted in the 2012 suit to determine identity of cause of action. | The later patents are part of the same transaction and accuse the same products/processes; preclusion applies. | Vacated and remanded: district court erred by not comparing asserted claim scopes; must apply the transactional/claim‑scope test (SimpleAir/Senju/Acumed). |
Key Cases Cited
- Alice Corp. v. CLS Bank Int’l, 573 U.S. 208 (established two‑step framework for § 101 abstraction analysis)
- Diamond v. Diehr, 450 U.S. 175 (applications of mathematical formulas in an improved industrial process are patent‑eligible)
- Thales Visionix Inc. v. United States, 850 F.3d 1343 (claims that use sensors and math in a nonconventional way to improve measurement accuracy are patent‑eligible)
- Parker v. Flook, 437 U.S. 584 (claims that merely recite a formula to update a number can be ineligible)
- Cleveland Clinic Found. v. True Health Diagnostics LLC, 859 F.3d 1352 (distinguishing observation of natural phenomena from improvements to laboratory techniques)
- SimpleAir, Inc. v. Google LLC, 884 F.3d 1160 (later‑filed continuation patents require claim‑scope comparison before concluding claim preclusion)
- Senju Pharm. Co. v. Apotex Inc., 746 F.3d 1344 (transactional test and patent‑case preclusion principles)
- Acumed LLC v. Stryker Corp., 525 F.3d 1319 (transactional facts include asserted patents and accused activity)
- Berkheimer v. HP Inc., 881 F.3d 1360 (§ 101 may present underlying factual issues; review is de novo)
- McRO, Inc. v. Bandai Namco Games Am. Inc., 837 F.3d 1299 (consider claims in their entirety to determine whether directed to an abstract idea)